Progress in Nanocarriers‐Based Approaches for the Delivery of Tyrosine Kinase Inhibitors in Bone Cancer: Trends and Prospects
Authors:
- 20 August 2025
- journal article
- review article
- Published by Wiley in IUBMB Life
- Vol. 77 (8) , e70052
Abstract
Bone cancer remains a life‐threatening malignancy predominantly affecting pediatric and adolescent populations, with tyrosine kinase inhibitors (TKIs) emerging as promising therapeutic agents; however, their clinical utility is limited by poor bioavailability, systemic toxicity, and inadequate tumor targeting. Recent advancements in nanocarrier‐based delivery systems have significantly mitigated these limitations by enhancing targeted accumulation of TKIs at tumor sites, reducing off‐target effects, and enabling controlled drug release. Various nanocarrier platforms, including liposomes, polymeric nanoparticles, micelles, dendrimers, metal‐ and metal oxide‐based nanoparticles, carbon‐based carriers, polymeric implants, and hydroxyapatite‐based systems, have been systematically evaluated for their efficacy in delivering TKIs for bone cancer therapy. This review further examines the impact of nanoparticle size on cellular uptake and tumor penetration, with emphasis on liposomal and proteinaceous carriers (albumin‐bound and transferrin‐conjugated nanoparticles) that optimize tumor selectivity while minimizing systemic toxicity. Inorganic nanocarriers such as gold, silver, and metal oxides also demonstrate potential for multimodal therapeutic and diagnostic applications. Notwithstanding these advances, challenges including drug resistance, toxicity, and regulatory barriers remain, necessitating ongoing efforts to optimize nanocarrier formulations. This comprehensive review provides critical insights into the evolving landscape of nanotechnology‐driven TKI delivery strategies aimed at enhancing therapeutic outcomes in bone cancer management.Keywords
This publication has 120 references indexed in Scilit:
- Microfluidic devices, materials, and recent progress for petroleum applications: A reviewThe Canadian Journal of Chemical Engineering, 2024
- Application of Hydrogels as Carrier in Tumor Therapy: A ReviewChemistry – An Asian Journal, 2022
- Nanotechnology-based targeted delivery systems for protein kinase inhibitors in Cancer therapy2022
- Bone and Soft Tissue Tumours2021
- Afatinib-loaded inhalable PLGA nanoparticles for localized therapy of non-small cell lung cancer (NSCLC)—development and in-vitro efficacyDrug Delivery and Translational Research, 2021
- Lapatinib-loaded acidity-triggered charge switchable polycarbonate-doxorubicin conjugate micelles for synergistic breast cancer chemotherapyActa Biomaterialia, 2020
- Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapyAsian Journal of Pharmaceutical Sciences, 2020
- Advanced development of ErbB family-targeted therapies in osteosarcoma treatmentInvestigational New Drugs, 2018
- Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET2018
- Tumor angiogenesis revisited: Regulators and clinical implicationsMedicinal Research Reviews, 2017